COVID-19 Vaccine (VLA2001)
COVID-19
ApprovedScaled Back
Key Facts
About Valneva SE
Valneva SE is a fully integrated specialty vaccine company with a mission to address unmet medical needs in infectious diseases through prophylactic vaccines. Its strategy combines proprietary technology platforms, including the EB66® cell line, with an end-to-end business model to control development, manufacturing, and commercialization. Key achievements include the launch of the world's only licensed chikungunya vaccine, a commercial portfolio for travel health, and a robust late-stage pipeline featuring a promising Lyme disease vaccine candidate in partnership with Pfizer.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |